TPTX Turning Point Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TPTX

Price (delayed)

$78.6

Market cap

$3.88B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.32

Enterprise value

$3.46B

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug ...

Highlights
The revenue has increased by 10% QoQ
TPTX's gross profit is up by 10% from the previous quarter
Turning Point Therapeutics's equity has soared by 50% YoY but it has decreased by 3.1% from the previous quarter
The EPS has contracted by 11% from the previous quarter but it has grown by 8% YoY
The debt has soared by 86% from the previous quarter and by 46% YoY
Turning Point Therapeutics's quick ratio has decreased by 46% YoY and by 26% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://tptherapeutics.com
Peers: OTIC ORIC

Key stats

What are the main financial stats of TPTX
Market
Shares outstanding
49.41M
Market cap
$3.88B
Enterprise value
$3.46B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.62
Price to sales (P/S)
69.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
62.56
Earnings
Revenue
$55.37M
EBIT
-$156.86M
EBITDA
-$154.16M
Free cash flow
-$91.13M
Per share
EPS
-$3.32
Free cash flow per share
-$1.85
Book value per share
$21.72
Revenue per share
$1.13
TBVPS
$22.42
Balance sheet
Total assets
$1.1B
Total liabilities
$35.41M
Debt
$6.5M
Equity
$1.07B
Working capital
$1.06B
Liquidity
Debt to equity
0.01
Current ratio
34.22
Quick ratio
33.79
Net debt/EBITDA
2.72
Margins
EBITDA margin
-278.4%
Gross margin
100%
Net margin
-283.3%
Operating margin
-287.5%
Efficiency
Return on assets
-15.3%
Return on equity
-15.8%
Return on invested capital
-27.9%
Return on capital employed
-14.6%
Return on sales
-283.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TPTX stock price

How has the Turning Point Therapeutics stock price performed over time
Intraday
0.76%
1 week
1.64%
1 month
17.77%
1 year
-5.19%
YTD
-35.49%
QTD
0.74%

Financial performance

How have Turning Point Therapeutics's revenue and profit performed over time
Revenue
$55.37M
Gross profit
$55.37M
Operating income
-$159.18M
Net income
-$156.86M
Gross margin
100%
Net margin
-283.3%
The net income has decreased by 19% QoQ and by 17% YoY
TPTX's operating income is down by 18% since the previous quarter and by 13% year-on-year
The revenue has increased by 10% QoQ
TPTX's gross profit is up by 10% from the previous quarter

Growth

What is Turning Point Therapeutics's growth rate over time

Valuation

What is Turning Point Therapeutics stock price valuation
P/E
N/A
P/B
3.62
P/S
69.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
62.56
The EPS has contracted by 11% from the previous quarter but it has grown by 8% YoY
Turning Point Therapeutics's equity has soared by 50% YoY but it has decreased by 3.1% from the previous quarter
TPTX's P/B is 21% below its last 4 quarters average of 4.6
The stock's price to sales (P/S) is 45% less than its last 4 quarters average of 127.0
The revenue has increased by 10% QoQ

Efficiency

How efficient is Turning Point Therapeutics business performance
Turning Point Therapeutics's ROA has increased by 43% YoY but it has decreased by 8% from the previous quarter
Turning Point Therapeutics's return on equity has increased by 43% YoY but it has decreased by 8% QoQ
The ROIC has grown by 36% YoY and by 2.8% from the previous quarter
The ROS has contracted by 8% from the previous quarter

Dividends

What is TPTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TPTX.

Financial health

How did Turning Point Therapeutics financials performed over time
The total liabilities has soared by 143% YoY and by 34% QoQ
TPTX's total assets has soared by 52% YoY but it is down by 2.2% from the previous quarter
The debt is 99% less than the equity
The debt has soared by 86% from the previous quarter and by 46% YoY
Turning Point Therapeutics's equity has soared by 50% YoY but it has decreased by 3.1% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.